Image
 

Locate Available Clinical Trials

To view available Clinical Trial information choose from the list on the right or search using the fields below.

 

 

trial #
trial description
  • Alliance A021502
  • The purpose of this study is to compare any good and bad effects of using the drug atezolizumab along with the usual chemotherapy compared to the usual chemotherapy alone. The addition of atezolizumab to the usual chemotherapy could prevent or reduce the chances of your colon cancer from returning, but it could also cause side effects. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the study drug would need to demonstrate increased chances of survival without the tumor returning by 10% or more compared to the usual approach. This drug, atezolizumab, is being tested in several types of cancer and has been granted FDA approval for its use in the treatment of bladder cancer. Atezolizumab is investigational for this study.  

  • Alliance N1048
  • The standard treatment for locally advanced rectal cancer involves the use of the chemotherapy drugs 5-fluorouracil and capecitabine plus radiation therapy prior to surgery. Although radiation therapy to the pelvis has been a standard and an important part of treatment for rectal cancer and has been shown to decrease the risk of the cancer coming back in the same area in the pelvis, some patients experience undesirable side effects from the radiation and there have been important advances in chemotherapy, surgery, and radiation which may be of benefit. The purpose of this study is to compare the effects, both good and bad, of the standard treatment of chemotherapy and radiation to chemotherapy using a combination regimen known as FOLFOX, (the drugs 5-fluorouracil, oxaliplatin, and leucovorin) and selective use of the standard treatment, depending on response to the FOLFOX.

  • CTSU EA2142
  • The purpose of this study is to compare the effects, both good and bad, of the study drugs temozolomide and capecitabine to the usual chemotherapy treatment for this disease of cisplatin and etoposide. Usually the first treatment given for this cancer is cisplatin and etoposide. The chemotherapy drugs temozolomide and capecitabine are also used to treat this disease but usually not until the first treatment, cisplatin and etoposide, stops working. It is not known if this is the best approach or if the temozolomide and capecitabine should be given first instead. The use of temozolomide and capecitabine could shrink your cancer but it could also cause side effects.

  • CTSU EA2165
  • The purpose of this study is to find if adding the study drug, nivolumab (also known as OPDIVO®), after standard chemotherapy {(mitomycin-C and 5-fluorouracil (5-FU) or capecitabine) or 5-FU and cisplatin} and radiation will prevent the anal cancer from returning. Nivolumab is a drug that may turn on the body’s immune system to attack any cancer cells that may remain after chemotherapy and radiation. The addition of nivolumab may help prevent your cancer from returning, but it could also cause side effects. This research study will allow researchers to find out whether this different treatment is better, the same, or worse than the usual treatment for anal cancer.

  • NRG GI002
  • The purpose of this study is to learn if adding an experimental drug, atezolizumab (MPDL3280A), to a usual treatment or giving the experimental drug alone is better than the usual treatment alone.  

  • NRG GI003
  • The purpose of this study is to compare any good and bad effects of using one of two kinds of radiation: proton therapy or photon therapy.

    Photon therapy, which uses high-energy x-rays to send the radiation inside the body to the tumor, is the most common radiation treatment approach for liver cancer.

    The other type of radiation is proton therapy, which uses a beam of protons (rather than x-rays) to send radiation inside the body to the tumor. This is the type of radiation therapy being studied in this trial.  Because protons act differently inside the body than x-rays, proton radiation may result in better survival. Both photon and proton therapy precisely deliver radiation to the tumor and use special images to help guide accurate delivery of a full dose of radiation to the tumor without damaging much of the healthy tissue around it.

    Both proton and photon therapy have already been tested for safety. Both types of radiation could shrink your cancer, but both could also cause side effects, and doctors and scientists do not know if one is better than the other or if they work equally well. This study will allow the researchers to know if proton radiation is better, the same, or worse than the photon radiation. 

  • NRG GI004
  • The purpose of this study is to learn if adding an experimental drug, atezolizumab (MPDL3280A), to a usual treatment or giving the experimental drug alone is better than the usual treatment alone.  The usual treatment in this study is the chemotherapy drugs, 5-flouorouracil (5-FU), leucovorin, and oxaliplatin. This combination is called FOLFOX.  In addition to FOLFOX, bevacizumab will be given.  Bevacizumab is in a group of drugs called biologic therapy.  FOLFOX and bevacizumab are approved by the FDA to treat metastatic CRC. To be better than FOLFOX and bevacizumab, atezolizumab given with FOLFOX and bevacizumab or atezolizumab given alone should keep your cancer from growing for more than 7 months.

     

    Another purpose of this study is to test the good and bad effects of atezolizumab when added to the usual treatment and when given alone.  Atezolizumab may keep your cancer from growing but it can also cause side effects.  Atezolizumab is FDA-approved for treating metastatic cancers of the bladder and lung.  Atezolizumab is considered experimental in this study because it is not approved to treat metastatic colorectal cancer. 

     

  • SWOG S0820
  • The purpose of this study is to determine if eflornithine and sulindac, taken alone or in combination, can decrease the risk of high-risk adenomas or second primary colorectal cancers in patients who have been treated for Stage 0, I, II or III colon cancer. 

  • SWOG S1613
  • The purpose of the treatment part of this study is to compare any good and bad effects of using a combination of antibodies, trastuzumab and pertuzumab, to using the usual chemotherapy, cetuximab and irinotecan to treat metastatic colorectal cancer. Treatment with antibodies could shrink your cancer, but it could also cause side effects. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. The antibody drug combination of trastuzumab and pertuzumab is already FDA-approved for use in HER-2 positive breast cancer. 

  • URCC 16092